Cancer Cell International





Oral presentation

Open Access

Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens

J Neudorfer*¹, B Schmidt¹, K Huster², M Schiemann², T Schmidt³, H Wagner², C Peschel¹, DH Busch² and H Bernhard¹

Address: ¹Department of Hematology/Oncology, Technical University of Munich, Munich, Germany, ²Department of Microbiology/Immunology Klinikum rechts der Isar, Technical University of Munich, Munich, Germany and ³IBA GmbH, Göttingen, Germany

Email: J Neudorfer* - julia.neudorfer@lrz.tu-muenchen.de

 $\it from$ Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2^{nd} Annual Meeting Mainz, Germany, 6–7 May 2004

Published: I July 2004 Received: 28 April 2004

Cancer Cell International 2004, 4(Suppl 1):S12

This article is available from: http://www.cancerci.com/content/4/S1/S12

Attempts to treat patients with tumor-reactive or viral-specific cytotoxic T lymphocytes (CTLs) have been limited due to the difficulty of isolating and expanding functionally active T cells present in low numbers in the peripheral blood. Recently developed MHC/peptide multimers mimic T cell receptor (TCR) ligands and, therefore, allow visualization and isolation of antigen-specific CTLs. However, the persistence of multimers leads to prolonged TCR signaling and subsequently to overstimulation and cell death. We have generated a new type of MHC/peptide multimers, termed streptamers, which can be dissociated from the TCR. In the mouse model, the dissociation of streptamers from the TCR, prevents T cells from multimerinduced cell death (Knabel et al. Nature Med 2002, 8:631). In this study, we investigate the efficacy of reversible HLA/ peptide multimers for isolation of human antigen-specific T cells. Melan-A and CMV have been chosen as representative tumor-associated and viral antigen (Ag), respectively. Specificity and reversibility of A2/CMV and A2/ Melan-A streptamers was documented by staining of Agspecific T cell clones and loss of staining after streptamer removal. Streptamer-stained Ag-specific T cells remained functionally active following dissociation, whereas lytic function of T cells was impaired in the presence of nonmultimers (tetramers). reversible Furthermore, CMVpp65(495-503)-specific T cells were streptamer- or tetramer-sorted from HLA-A2-positive, CMV-seropositive donors either directly out of the blood or following repetitive peptide stimulations in vitro. Both attempts successfully led to the isolation of CMV-specific CTLs that were cloned by limiting dilution. Clonal proliferation was superior for CMV-specific streptamer-sorted T cells compared to tetramer-sorted T cells. CMV-specific T cell clones isolated with streptamers and tetramers displayed a similar TCR repertoire and avidity. Growing CTL clones were capable of lysing CMVpp65(495-503)-pulsed as well as CMVpp65-transfected HLA-A2-positive target cells. For isolation of melanoma-reactive CTLs, the modified decapeptide Melan-A(26-35)A27L was chosen to construct streptamers respective tetramers. Again, streptamersorted Melan-A-specific CTL clones proliferated better than tetramer-sorted CTL clones. The isolated Melan-Aspecific CTL clones displayed different TCR motifs, which can be explained by the broad repertoire of Melan-A-specific T cells physiologically present in vivo. All Melan-A(26-35)A27L-specific CTL clones crossreacted with the naturally processed peptide Melan-A(27-35), but only some CTL clones lysed HLA-A2-matched, Melan-Aexpressing melanoma cells. Of note, tumor recognition by some streptamer-sorted CTL clones was superior to tumor lysis by tetramer-sorted CTL clones. Our current experiments focus on the isolation of T cells using reversible multimers coupled with microbeads allowing us to sort antigen-specific T cells under the guidelines of good manufacturing practice. Clinical goal is the adoptive transfer of

^{*} Corresponding author

antigen-specific T lymphocytes for treatment of patients with cancer or infectious diseases.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- \bullet peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- \bullet yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp

